Truist raised the firm’s price target on RadNet to $51 from $42 and keeps a Buy rating on the shares. The firm cites the companyh’s Q4 results that beat on the top and bottom lines, driven by “brisk advanced procedure growth, better than expected margins and attractive flow”. RadNet is well positioned to benefit from several overarching tailwinds, with a robust and potentially accelerating M&A opportunity and financial flexibility remaining attractive, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDNT:
- Options Volatility and Implied Earnings Moves Today, March 01, 2024
- RadNet sees FY24 revenue $1.65B-$1.7B, consensus $1.72B
- RadNet reports Q4 adjusted EPS 20c, consensus 15c
- RadNet Reports Fourth Quarter 2023 Results, Including Record Revenue and Adjusted EBITDA(1), Releases 2024 Financial Guidance and Forms a New Digital Health Reporting Segment
- RDNT Earnings Report this Week: Is It a Buy, Ahead of Earnings?